Amendments to the Claims:

Please amend claims 81-83 as shown, below.

The following listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claims 1-74 (Canceled).

Claim 75 (Previously presented): A compound of formula A or B:

wherein

R^{4"} is selected from the group consisting of hydrogen and alkyl;

R⁵ is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclic, substituted heterocylic, heteroaryl and substituted heteroaryl;

R⁶ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, substituted cycloalkenyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and –SO₂R¹⁰ where R¹⁰ is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl,

025.15677.1 -2-

cycloalkenyl, substituted cycloalkenyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl;

R⁷ and R⁸ are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heterocyclic and halogen;

R¹¹ and R^{11'} are independently selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkenyl, substituted cycloalkenyl, heterocyclic, substituted heterocyclic, and where R¹¹ and R^{11'} are joined to form a heterocycle or a substituted heterocycle;

R¹⁶ is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and halogen; and

R¹⁸ is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, cycloalkyl, substituted cycloalkyl, nitro, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic;

R²⁰ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heterocyclic, substituted heterocyclic and halogen;

X is selected from the group consisting of hydroxyl, alkoxy, substituted alkoxy, alkenoxy, substituted alkenoxy, cycloalkoxy, substituted cycloalkoxy, cycloalkenoxy, substituted cycloalkenoxy, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy and—NR "R" where each R" is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted

alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heterocyclic;

x is an integer of from 0 to 4.

or enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

Claim 76 (Previously presented): The compound of claim 75, wherein the compound is selected from formula B.

Claim 77 (Previously presented): The compound of claim 75, wherein R⁴" is hydrogen.

Claim 78 (Previously presented): A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a pharmaceutically effective amount of a compound of Claim 75.

Claim 79 (Previously presented): A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a pharmaceutically effective amount of a compound of Claim 76.

Claim 80 (Previously presented): A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a pharmaceutically effective amount of a compound of Claim 77.

Claim 81 (Currently amended): A method for treating inflammation in a mammalian patient which inflammation is mediated by VLA-4, which method comprises administering to said patient a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a pharmaceutically effective amount of a eompound pharmaceutical composition of Claim 78.

Claim 82 (Currently amended): A method for treating inflammation in a mammalian patient which inflammation is mediated by VLA-4, which method comprises administering to said patient a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a pharmaceutically effective amount of a compound pharmaceutical composition of Claim 79.

Claim 83 (Currently amended): A method for treating inflammation in a mammalian patient which inflammation is mediated by VLA-4, which method comprises administering to said patient a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a pharmaceutically effective amount of a eompound pharmaceutical composition of Claim 80.